Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Haemophilia care in Iraq; a multi-centre study

View through CrossRef
Objectives: To evaluate the level of care available to haemophilia patients. Method: The descriptive, retrospective analytical study was conducted from December 15, 2020, to March 1, 2021, after approval from the Mustansiriyah University, Baghdad, Iraq, and comprised data from 3 haemophilia treating centres in Iraq participating in the World   Bleeding Disorders Registry. The data collected related to patients with haemophilia A and B enrolled in the registry since March 2018, and included age at diagnosis, type of haemophilia, disease severity, age at first bleed and at first joint bleed, type of replacement therapy and outcome. Data was analysed using statistical package of social sciences (SPSS) version 20. Results: Of the 638 patients with mean age 16.2±4.3 (range: 9-29 years), 581(91%) had haemophilia A, 57(8.9%) had haemophilia B, 385(60.5%) had severe haemophilia, 126(19.8%) moderate and 125(19.7%) mild. Further, 259(41%) patients had been diagnosed for <1 year. There were 1354 bleeding events, and hemarthrosis accounted for 959(70.8%) of them. The mean annualised bleeding rate for severe patients was  2 ± 0.6(range 0-4), while the mean annualised joint bleeding rate was 4 ± 1.3(range :2-8). There were 256(32.3%) patients who were tested for inhibitors, and 62(24.3%) were positive. Among 426(73.3%) haemophilia A patients with a treatment history, 248(58%) were on prophylactic therapy, and the corresponding value among 37(65%) haemophilia B patients was 17(46%). Conclusions: access to treatment was found to be limited, and patients were found to be suffering from high bleeding rates and joint damage. Key Words: Haemophilia A and B, Hemarthrosis, Health Services, Acuity
Title: Haemophilia care in Iraq; a multi-centre study
Description:
Objectives: To evaluate the level of care available to haemophilia patients.
Method: The descriptive, retrospective analytical study was conducted from December 15, 2020, to March 1, 2021, after approval from the Mustansiriyah University, Baghdad, Iraq, and comprised data from 3 haemophilia treating centres in Iraq participating in the World   Bleeding Disorders Registry.
The data collected related to patients with haemophilia A and B enrolled in the registry since March 2018, and included age at diagnosis, type of haemophilia, disease severity, age at first bleed and at first joint bleed, type of replacement therapy and outcome.
Data was analysed using statistical package of social sciences (SPSS) version 20.
Results: Of the 638 patients with mean age 16.
2±4.
3 (range: 9-29 years), 581(91%) had haemophilia A, 57(8.
9%) had haemophilia B, 385(60.
5%) had severe haemophilia, 126(19.
8%) moderate and 125(19.
7%) mild.
Further, 259(41%) patients had been diagnosed for <1 year.
There were 1354 bleeding events, and hemarthrosis accounted for 959(70.
8%) of them.
The mean annualised bleeding rate for severe patients was  2 ± 0.
6(range 0-4), while the mean annualised joint bleeding rate was 4 ± 1.
3(range :2-8).
There were 256(32.
3%) patients who were tested for inhibitors, and 62(24.
3%) were positive.
Among 426(73.
3%) haemophilia A patients with a treatment history, 248(58%) were on prophylactic therapy, and the corresponding value among 37(65%) haemophilia B patients was 17(46%).
Conclusions: access to treatment was found to be limited, and patients were found to be suffering from high bleeding rates and joint damage.
Key Words: Haemophilia A and B, Hemarthrosis, Health Services, Acuity.

Related Results

Treatment trends for haemophilia A and haemophilia B in the United States: results from the 2010 practice patterns survey
Treatment trends for haemophilia A and haemophilia B in the United States: results from the 2010 practice patterns survey
Summary.  Frequent evaluation of haemophilia treatment is necessary to improve patient care. The 2010 Practice Patterns Survey (PPS) investigated current trends in haemophilia trea...
A preliminary application of a haemophilia value framework to emerging therapies in haemophilia
A preliminary application of a haemophilia value framework to emerging therapies in haemophilia
AbstractIntroductionEmergence of new therapies are anticipated to improve clinical outcomes and quality of life of persons with haemophilia. Challenges in conducting randomized cli...
A transgender person with haemophilia
A transgender person with haemophilia
Abstract Introduction Transgender people face many obstacles to accessing healthcare but cultural changes are likely to i...
Osoby niejednokrotnie przebywające w izbie wytrzeźwień
Osoby niejednokrotnie przebywające w izbie wytrzeźwień
In Poland we have at present in towns 29 detoxication centres with 1,226 beds; people found by the police in public places in a state of intoxication are more and more often taken ...
Haemophilia treatment in 2030
Haemophilia treatment in 2030
IntroductionLooking into the future is difficult and sometimes hazardous. A reliable look into haemophilia treatment in 2030 should be based on history and contemporary progress as...
Normalisation of Haemostasis in Haemophilia A
Normalisation of Haemostasis in Haemophilia A
Haemophilia A (Factor VIII [FVIII] levels ≤40 IU/dL) is a chronic condition with consequences beyond bleeding complications. Many people with haemophilia A (PwHA) experience pain, ...
UKHCDO gene therapy taskforce: Guidance for implementation of haemophilia gene therapy into routine clinical practice for adults
UKHCDO gene therapy taskforce: Guidance for implementation of haemophilia gene therapy into routine clinical practice for adults
AbstractIntroduction2022 was a landmark year with two adeno‐associated viral vectors (AAVs) receiving conditional marketing authorization from EMA for the treatment of persons with...

Back to Top